Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Budgeting is essential for young adults seeking financial stability. Learn its importance in securing your financial future.
19,159 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
The FCC is weighing a Know Your Customer style rule that would tie identity to every phone line. Privacy advocates wa...
Avis Budget Group stock surged this week as travel demand picked up and airport bottlenecks nudged customers toward r...
Investors who missed CrowdStrike’s rally found a diversified path higher, as a cybersecurity ETF posted 29% gains ove...
When margins rebound in the energy sector, even senior executives may trim holdings to align with evolving risk and o...
SpaceX dazzled investors at IPO, but the price soon drifted below debut. This article shows how a $10,000 investment ...
Investors are flocking to renewable energy stocks as policy support and expanding clean-energy projects push the sect...
The Nasdaq Composite rises as cooling inflation and strong chip profits lift tech shares, setting the tone for a summ...
Gas prices surged this week, lifting the national average price by about 33 cents. The rise comes as refinery mainten...
As AI infrastructure spending stays robust, memory names SanDisk and Micron pursue starkly different paths. SanDisk l...
Oil weakness and a tech-led stock rally push the VIX toward the 17 level as traders return to equities.
Policy clarity clears the path for road ahead build-to-rent projects, lifting investor confidence. Still, the pace of...